Novel HMGB1-inhibiting therapeutic agents for experimental sepsis

Shock

Volumn 32, Issue 4, 2009, Pages 348-357

  Wang, Haichao ^a,b   Ward, Mary F ^b   Sama, Andrew E ^b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Antibodies; Cytokines; HMGB1; Inflammation; Innate immune cells; Phagocytes; Sepsis; Tanshinones

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ANGELICA SINENSIS EXTRACT; ANTITHROMBIN III; CHOLINE; ENDOTOXIN; EPIGALLOCATECHIN GALLATE; ETHYLPYRUVIC ACID; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; GHRELIN; GREEN TEA EXTRACT; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; HYDROLASE; IMMUNOGLOBULIN G; INSULIN; LYSOPHOSPHATIDYLCHOLINE; NEUTRALIZING ANTIBODY; NICOTINE; PROTEIN INHIBITOR; PYRUVIC ACID DERIVATIVE; REACTIVE OXYGEN METABOLITE; SALVIA MILTIORRHIZA EXTRACT; STEAROYLLYSOPHOSPHATIDYLCHOLINE; TANSHINONE IIA; THROMBOMODULIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

APOPTOSIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CLINICAL TRIAL; DOSE RESPONSE; ENDOTOXEMIA; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE INJURY; TISSUE REGENERATION; TISSUE REPAIR; VAGUS NERVE STIMULATION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; MACROPHAGES; SEPSIS;

EID: 67650493786     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181a551bd     Document Type: Review

References (144)

1. Wang H, Zhu S, Zhou R, Li W, Sama AE: Therapeutic potential of HMGB1- targeting agents in sepsis. Expert Rev Mol Med 10:e32, 2008.
2. Serhan CN, Savill J: Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191-1197, 2005.
3. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296-327, 2008.
4. Luster AD, Alon R, von Andrian UH: Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 6:1182-1190, 2005.
5. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA: The neutrophil as a cellular source of chemokines. Immunol Rev 177:195-203, 2000.
6. Mosser DM: Receptors on phagocytic cells involved in microbial recognition. Immunol Ser 60:99-114, 1994.
7. Wu Y, Tibrewal N, Birge RB: Phosphatidylserine recognition by phagocytes: a view to a kill. Trends Cell Biol 16:189-197, 2006.
8. Liles WC: Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases. Semin Respir Infect 16:11-17, 2001.
9. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, Maitland M, Norgard MV, Plevy SE, Smale ST, et al.: Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science 285:732-736, 1999.
10. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088, 1998.
11. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al.: A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745, 2000.
12. Krieg AM: CpG motifs in bacterial DNA and thei'r immune effects. Annu Rev Immunol 20:709-760, 2002.
13. Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol 4:499-511, 2004.
14. Baggiolini M, Loetscher P: Chemokines in inflammation and immunity. Immunol Today 21:418-420, 2000.
15. Balkwill F: CytokinesVsoluble factors in immune responses. Curr Opin Immunol 1:241-249, 1988.
16. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shockVa review of laboratory models and a proposal. J Surg Res 29:189-201, 1980.
17. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664, 1987.
18. Dinarello CA, Thompson RC: Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12:404-410, 1991.
19. Heinzel FP: The role of IFN-γ in the pathology of experimental endotoxemia. J Immunol 145:2920-2924, 1990.
20. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164-170, 2000.
21. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR: Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189:341-346, 1999.
22. Davis CE, Brown KR, Douglas H, Tate WJ, III, Braude AI: Prevention of death from endotoxin with antisera. I. The risk of fatal anaphylaxis to endotoxin. J Immunol 102:563-572, 1969.
23. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251, 1999.
24. Ferrari S, Ronfani L, Calogero S, Bianchi ME: The mouse gene coding for high mobility group 1 protein (HMG1). J Biol Chem 269:28803-28808, 1994.
25. Paonessa G, Frank R, Cortese R: Nucleotide sequence of rat liver HMG1 cDNA. Nucleic Acids Res 15:9077, 1987.
26. Johns EW: History, Definitions and Problems. In: Johns EW, ed.: The HMG Chromosomal Proteins. London, UK: Academic Press Inc. (London) Ltd, 1-8, 1982.
27. Bustin M: Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 26:152-153, 2001.
28. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22:5551-5560, 2003.
29. Wen L, Huang JK, Johnson BH, Reeck GR: A human placental cDNA clone that encodes nonhistone chromosomal protein HMG-1. Nucleic Acids Res 17:1197-1214, 1989.
30. Bustin M: At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci STKE (151): PE39, 2002.
31. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101: 296-301, 2004.
32. Lang CH, Silvis C, Deshpande N, Nystrom G, Frost RA: Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor α, interleukin-1γ, -6, and high-mobility-group proteinY1 in skeletal muscle. Shock 19:538-546, 2003.
33. Fang WH, Yao YM, Shi ZG, Yu Y, Wu Y, Lu LR, Sheng ZY: The significance of changes in high mobility groupY1 protein mRNA expression in rats after thermal injury. Shock 17:329-333, 2002.
34. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ: HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164: 1768-1773, 2001.
35. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ: Persistent elevation of high mobility group boxY1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33:564-573, 2005.
36. Angus DC, Yang L, Kong L, Kellum JA, Delude RL, Tracey KJ, Weissfeld L: Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 35:1061-1067, 2007.
37. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, et al.: The N-terminal domain of thrombomodulin sequesters high-mobility groupYB1 protein, a novel antiinflammatory mechanism. J Clin Invest 115:1267-1274, 2005.
38. Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE: Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 81:67-74, 2007.
39. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, et al.: Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 203:1637-1642, 2006.
40. O'Connor KA, Hansen MK, Rachal PC, Deak MM, Biedenkapp JC, Milligan ED, Johnson JD, Wang H, Maier SF, Tracey KJ, et al.: Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects. Cytokine 24:254-265, 2003.
41. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP: HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123:790-802, 2002.
42. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ: HMG-1 as a mediator of acute lung inflammation. J Immunol 165:2950-2954, 2000.
43. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, et al.: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170:1310-1316, 2004.
44. Lin X, Yang H, Sakuragi T, Hu M, Mantell LL, Hayashi S, Al Abed Y, Tracey KJ, Ulloa L, Miller EJ: {!}-Chemokine receptor blockade reduces high mobility group box 1 proteinYinduced lung inflammation and injury and improves survival in sepsis. Am J Physiol Lung Cell Mol Physiol 289: L583-L590, 2005.
45. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy J, et al.: Potential role of high mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 178(8):822-831, 2008.
46. Agnello D, Wang H, Yang H, Tracey KJ, Ghezzi P: HMGB1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine 18:231-236, 2002.
47. Pedrazzi M, Raiteri L, Bonanno G, Patrone M, Ledda S, Passalacqua M, Milanese M, Melloni E, Raiteri M, Pontremoli S, et al.: Stimulation of excitatory amino acid release from adult mouse brain glia subcellular particles by high mobility group box 1 protein. J Neurochem 99:827-838, 2006.
48. Chacur M, Milligan ED, Gazda LS, Armstrong C, Wang H, Tracey KJ, Maier SF, Watkins LR: A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain 94:231-244, 2001.
49. van Zoelen MA, Yang H, Florquin S, Meijers JC, Akira S, Arnold B, Nawroth PP, Bierhaus A, Tracey KJ, van der PT: Role of Toll-like receptors 2 and 4, and the receptor for advanced glycation end products (RAGE) in HMGB1 induced inflammation in vivo. Shock 31:280-284, 2009.
50. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, et al.: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201:1135-1143, 2005.
51. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ: TLR4 activation mediates kidney ischemia/ reperfusion injury. J Clin Invest 117:2847-2859, 2007.
52. Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T, Sato Y, Hiraga N, Adachi N, Yoshino T, et al.: Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21:3904-3916, 2007.
53. Yang R, Harada T, Mollen KP, Prince JM, Levy RM, Englert JA, Gallowitsch-Puerta M, Yang L, Yang H, Tracey KJ, et al.: Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med 12:105-114, 2006.
54. Peltz ED, Moore EE, Eckels PC, Damle SS, Tsuruta Y, Johnson JL, Sauaia A, Silliman CC, Banerjee A, Abraham E: HMGB1 is markedly elevated within six hours of mechanical trauma in humans. Shock 32:17-22, 2008.
55. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, et al.: High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117:3216-3226, 2008.
56. Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey KJ, Bendszus M, Rossetti G, Nawroth PP, Bierhaus A, et al.: The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 28: 12023-12031, 2008.
57. Ogawa EN, Ishizaka A, Tasaka S, Koh H, Ueno H, Amaya F, Ebina M, Yamada S, Funakoshi Y, Soejima J, et al.: Contribution of high-mobility group boxY1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med 174:400-407, 2006.
58. Sawa H, Ueda T, Takeyama Y, Yasuda T, Shinzeki M, Nakajima T, Kuroda Y: Blockade of high mobility group boxY1 protein attenuates experimental severe acute pancreatitis. World J Gastroenterol 12:7666-7670, 2006.
59. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME: Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164:441-449, 2004.
60. Li W, Sama AE, Wang H: Role of HMGB1 in cardiovascular diseases. Curr Opin Pharmacol 6:130-135, 2006.
61. Kohno T, Anzai T, Naito K, Miyasho T, Okamoto M, Yokota H, Yamada S, Maekawa Y, Takahashi T, Yoshikawa T, et al.: Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 81(3):565-573, 2009.
62. Takahashi K, Fukushima S, Yamahara K, Yashiro K, Shintani Y, Coppen SR, Salem HK, Brouilette SW, Yacoub MH, Suzuki K: Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation 118:S106-S114, 2008.
63. Oppenheim JJ, Yang D: Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 17:359-365, 2005.
64. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, Sitia G, Yap GS, Wan Y, Biron CA, et al.: A novel role for HMGB1 in TLR9- mediated inflammatory responses to CpG-DNA. Blood 110(6):1970-1981, 2007.
65. Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, Susarla S, Czura C, Mitchell RA, Chen G, et al.: IFN-γ induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 170:3890-3897, 2003.
66. Tang D, Shi Y, Kang R, Li T, Xiao W, Wang H, Xiao X: Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 81:741-747, 2007.
67. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A: The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3:955-1001, 2002.
68. Youn JH, Shin JS: Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol 177:7889-7897, 2006.
69. Zhang X, Wheeler D, Tang Y, Guo L, Shapiro RA, Ribar TJ, Means AR, Billiar TR, Angus DC, Rosengart MR: Calcium/calmodulin-dependent protein kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages. J Immunol 181:5015-5023, 2008.
70. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-195, 2002.
71. Chu JJ, Ng ML: The mechanism of cell death during West Nile virus infection is dependent on initial infectious dose. J Gen Virol 84:3305-3314, 2003.
72. Joseph T, Cepica A, Brown L, Ikede BO, Kibenge FS: Mechanism of cell death during infectious salmon anemia virus infection is cell type-specific. J Gen Virol 85:3027-3036, 2004.
73. Chen LC, Yeh TM, Wu HN, Lin YY, Shyu HW: Dengue virus infection induces passive release of high mobility group box 1 protein by epithelial cells. J Infect 56:143-150, 2008.
74. Alleva LM, Budd AC, Clark IA: Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol 181:1454-1459, 2008.
75. Hofner P, Seprényi G, Miczák A, Buzás K, Gyulai Z, Medzihradszky KF, Rouhiainen A, Rauvala H, Mándi Y: High mobility group box 1 protein induction by Mycobacterium bovis BCG. Mediators Inflamm 2007:53805.
76. Grover A, Taylor J, Troudt J, Keyser A, Sommersted K, Schenkel A, Izzo AA: Mycobacterial infection induces the secretion of high-mobility group box 1 protein. Cell Microbiol 10:1390-1404, 2008.
77. Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H: Regulation of cell migration by amphoterin. J Cell Sci 113(Pt 4):611-620, 2000.
78. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, Arrigoni G, Bianchi ME: The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152:1197-1206, 2001.
79. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H: Receptor for advanced glycation end productsYbinding COOHYterminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62:4805-4811, 2002.
80. Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, Bianchi ME: Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 179:33-40, 2007.
81. Rouhiainen A, Kuja-Panula J, Wilkman E, Pakkanen J, Stenfors J, Tuominen RK, Lepantalo M, Carpen O, Parkkinen J, Rauvala H: Regulation of monocyte migration by amphoterin (HMGB1). Blood 104:1174-1182, 2004.
82. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ: High mobility group boxY1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 81:59-66, 2007.
83. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P: The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 81:84-91, 2007.
84. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP, et al.: A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1- integrin. EMBO J 26:1129-1139, 2007.
85. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, Arrigoni G, Bianchi ME: The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152:1197-1206, 2001.
86. Degryse B, de Virgilio M: The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett 553:11-17, 2003.
87. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, et al.: Toll-like receptor 9Ydependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8:487-496, 2007.
88. Silva E, Arcaroli J, He Q, Svetkauskaite D, Coldren C, Nick JA, Poch K, Park JS, Banerjee A, Abraham E: HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsisinduced acute lung injury. Intensive Care Med 33:1829-1839, 2007.
89. Sha Y, Zmijewski J, Xu Z, Abraham E: HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 180: 2531-2537, 2008.
90. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, et al.: Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 205:3007-3018, 2008.
91. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E: Involvement of TLR 2 and TLR 4 in cellular activation by high mobility group box 1 protein (HMGB1). J Biol Chem 279:7370-7377, 2004.
92. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H: HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2. Shock 26:174-179, 2006.
93. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al.: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290:C917YC924, 2006.
94. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61:1-9, 2005.
95. Pedrazzi M, Patrone M, Passalacqua M, Ranzato E, Colamassaro D, Sparatore B, Pontremoli S, Melloni E: Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J Immunol 179:8525-8532, 2007.
96. Yamoah K, Brebene A, Baliram R, Inagaki K, Dolios G, Arabi A, Majeed R, Amano H, Wang R, Yanagisawa R, et al.: High-mobility group box proteins modulate tumor necrosis factorY! expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence. Mol Endocrinol 22:1141-1153, 2008.
97. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101:2652-2660, 2003.
98. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, et al.: High mobility group 1 BYbox mediates activation of human endothelium. J Intern Med 254:375-385, 2003.
99. Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE: Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 48:2052-2058, 2003.
100. Yang H, Wang H, Tracey KJ: HMG-1 rediscovered as a cytokine. Shock 15:247-253, 2001.
101. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, Harris HE, Czura CJ, Wang H, Ulloa L, et al.: Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 9:37-45, 2003.
102. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, Tracey KJ, Chiorazzi N: High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173:307-313, 2004.
103. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA: Induction of immunological tolerance by apoptotic cells requires caspasedependent oxidation of high-mobility group boxY1 protein. Immunity 29:21-32, 2008.
104. Liu G, Wang J, Park YJ, Tsuruta Y, Lorne EF, Zhao X, Abraham E: High mobility group proteinY1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 181:4240-4246, 2008.
105. Bell CW, Jiang W, Reich CF, Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 291(6): C1318-C1325, 2006.
106. Yin K, Gribbin E, Wang H: Interferon-+ inhibition attenuates lethality after cecal ligation and puncture in rats: implication of high mobility group box-1. Shock 24:396-401, 2005.
107. Hagiwara S, Iwasaka H, Hasegawa A, Asai N, Noguchi T: High-dose intravenous immunoglobulin G improves systemic inflammation in a rat model of CLP-induced sepsis. Intensive Care Med 34(10):1812-1819, 2008.
108. Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T: High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med 34:361-367, 2008.
109. Hagiwara S, Iwasaka H, Hasegawa A, Koga H, Noguchi T: Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med 36:2407-2413, 2008.
110. Wang H, Zhu S, Ward MF, Gong J, Sama AE: Hyperglycemia aggravates endotoxin-induced high mobility group box 1 protein release: yet another reason not to be too sweet. Crit Care Med 36:2475-2476, 2008.
111. Chorny A, Delgado M: Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 172:1297-1307, 2008.
112. Tang Y, Lv B, Wang H, Zuo X, Xiao X: PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia. Int Immunopharmacol 8:1646-1651, 2008.
113. Wu R, Dong W, Zhou M, Zhang F, Marini CP, Ravikumar TS, Wang P: Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am J Respir Crit Care Med 176:805-813, 2007.
114. Wu R, Dong W, Cui X, Zhou M, Simms HH, Ravikumar TS, Wang P: Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg 245:480-486, 2007.
115. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M: Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol 180:8369-8377, 2008.
116. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405:458-462, 2000.
117. Huston JM, Ochani M, Rosas-Ballina M, Liao H, Ochani K, Pavlov VA, Gallowitsch-Puerta M, Ashok M, Czura CJ, Foxwell B, et al.: Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 203:1623-1628, 2006.
118. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al Abed Y, Wang H, Metz C, Miller EJ, et al.: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10:1216-1221, 2004.
119. Pavlov VA, Ochani M, Yang LH, Gallowitsch-Puerta M, Ochani K, Lin X, Levi J, Parrish WR, Rosas-Ballina M, Czura CJ, et al.: Selective α7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 35:1139-1144, 2007.
120. Parrish WR, Rosas-Ballina M, Gallowitsch-Puerta M, Ochani M, Ochani K, Yang LH, Hudson L, Lin X, Patel N, Johnson SM, et al.: Modulation of TNF release by choline requires α7 subunit nicotinic acetylcholine receptorYmediated signaling. Mol Med 14:567-574, 2008.
121. Huston JM, Gallowitsch-Puerta M, Ochani M, Ochani K, Yuan R, Rosas- Ballina M, Ashok M, Goldstein RS, Chavan S, Pavlov VA, et al.: Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med 35:276-2768, 2007.
122. Li W, Li J, Ashok M, Wu R, Chen D, Yang L, Yang H, Tracey KJ, Wang P, Sama AE, et al.: A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 178:3856-3864, 2007.
123. Li W, Ashok M, Li J, Yang H, Sama AE, Wang H: A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS ONE 2:e1153, 2007.
124. Wheeler DS, Lahni PM, Hake PW, Denenberg AG, Wong HR, Snead C, Catravas JD, Zingarelli B: The green tea polyphenol epigallocatechin-3- gallate improves systemic hemodynamics and survival in rodent models of polymicrobial sepsis. Shock 28:353-359, 2007.
125. Fink MP: Ethyl pyruvate: a novel treatment for sepsis. Curr Drug Targets 8:515-518, 2007.
126. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ: Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 99:12351-12356, 2002.
127. Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, et al.: Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10:161-167, 2004.
128. Wang H, Czura CJ, Tracey KJ: Lipid unites disparate syndromes of sepsis. Nat Med 10:124-125, 2004.
129. Chen G, Li J, Qiang X, Czura CJ, Ochani M, Ochani K, Ulloa L, Yang H, Tracey KJ, Wang P, et al.: Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 46:623-627, 2005.
130. Pahuja M, Tran C, Wang H, Yin K: Alveolar macrophage suppression in sepsis is associated with high mobility group box a transmigration. Shock 29(6):754-760, 2008.
131. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238-247, 2003.
132. Zhu S, Li W, Li J, Sama AE, Wang H: Caging a beast in the inflammation arena: use of Chinese medicinal herbs to inhibit a late mediator of lethal sepsis, HMGB1. Intern J Clin Exp Med 1:64-79, 2008.
133. Wang H, Li W, Li J, Rendon-Mitchell B, Ochani M, Ashok M, Yang L, Yang H, Tracey KJ, Wang P, et al.: The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J Nutr 136:360-365, 2006.
134. Osuchowski MF, Welch K, Siddiqui J, Remick DG: Circulating cytokine/ inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 177:1967-1974, 2006.
135. Ji XY, Tan BK, Zhu YZ: Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin 21:1089-1094, 2000.
136. Cheng TO: Cardiovascular effects of Danshen. Int J Cardiol 121:9-22, 2007.
137. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871, 1985.
138. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, et al.: Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324:429-436, 1991.
139. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225-1230, 1982.
140. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R: Efficacy and safety of monoclonal antibody to human tumor necrosis factor ! in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-α MAb Sepsis Study Group. JAMA 273:934-941, 1995.
141. Cohen J: Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. Br Med Bull 55:212-225, 1999.
142. Mantell LL, Parrish WR, Ulloa L: Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25:4-11, 2006.
143. Wang H, Yang H, Tracey KJ: Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255:320-331, 2004.
144. Tzeng HP, Fan J, Vallejo JG, Dong JW, Chen X, Houser SR, Mann DL: Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. Am J Physiol Heart Circ Physiol 294: H1490-H1496, 2008.